JMJulia Martínez-Barrio

Julia Martínez-Barrio

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julia Martínez-Barrio has a total of 252 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Self-reported depression on the Lupus Impact Tracker questionnaire (LIT) is associated with glucocorticoid use and fibromyalgia in systemic lupus erythematosus, according to RELESSER-PROS registry data

    by Inigo Rua-Figueroa, Julia Martínez-Barrio, Zulema Plaza, Norman Jiménez, Maria Galindo-Izquierdo, Esther Uriarte, Antonio Fernandez-Nebro, Jaime Calvo Alen, José Rosas, Javier Narváez, et al.

    To assess the prevalence and persistence of self-reported depression and its associated factors in patients with systemic lupus erythematosus (SLE), using

  • Open Access

    Improving early referrals for inflammatory arthritis through primary care engagement: a quality improvement initiative

    by Camille Bourgeois, Marina Sánchez-Lucas, Jorge Olmedo-Galindo, María Teresa Schiaffino, Tamara del Río, Juan Molina-Collada, Julia Martínez-Barrio, Gema Fernández-Plana, Javier Rivera, Jose María Álvaro-Gracia, et al.

    Objectives: Early rheumatology referral is crucial for optimal outcomes in inflammatory arthritis, but delays remain common. This quality improvement (QI) project aimed to identify barriers and implement strategies to improve referral adequacy and timeliness within a newly established early referral program. Despite the implementation of a direct referral pathway for primary care physicians, many patients did not meet eligibility criteria, limiting access for those with early inflammatory arthritis. Methods: Since January 2022, a 1 day/week early arthritis clinic has offered direct and rapid access to rheumatology appointments to 180 primary care physicians (PCPs) across 11 centres. Standardized referral criteria were co-developed with a PCPs committee. A survey assessed PCPs’ confidence, perceived barriers and educational needs using Likert scales and open-ended responses. In response to survey findings, electronic consultations (e-consults), concise referral guidelines and targeted training materials were introduced to support appropriate referrals. Results: Within the first year, the median referral time decreased from 51 to 15 days, although only 21% of referrals met the criteria. Most PCPs recognized the importance of early diagnosis (67%) but reported limited confidence in managing suspected cases (96% partially or not confident). Reported barriers included non-specific symptoms (48%) and long rheumatology wait times (39%). PCPs expressed strong interest in e-consults (87%) and brief educational tools (78%). Conclusion: This QI initiative reduced referral delays and identified key barriers to effective early arthritis referrals, including PCPs lack confidence in diagnosis and long rheumatologist wait times. Enhancing communication through e-consults and targeted educational resources may optimize early referral.


  • Diffuse alveolar hemorrhage in patients with systemic lupus erythematosus: data from the Spanish society of rheumathology Lupus Register (RELESSER)

    by María Jesús Garcia-Villanueva, Sandra Garrote-Corral, Jose María Pego-Reigosa, Norman Jiménez Otero, Esther Uriarte Isazelaia, Alejandro Olivé Marqué, Clara Sangüesa Gómez, Mercedes Freire González, Elena Aurrecoechea Aguinaga, Enrique Raya Álvarez, et al.

    Introduction: Diffuse alveolar hemorrhage (DAH) is a rare complication with high mortality in patients with systemic lupus erythematosus (SLE). Early diagnosis and treatment are essential to improve patient prognosis. To determine the characteristics of patients with DAH and their mortality in a Spanish cohort of patients with SLE. Methods: Patients from the RELESSER (Spanish Society of Rheumatology Lupus Register) who had had at least one confirmed episode of DAH were included. Epidemiological, clinical, and laboratory characteristics were analyzed. Results: 4024 patients were included in the RELESSER register, 37 (0.9%), had at least one recorded episode of DAH. Only further data for 14 patients could be analyzed. In total, 92.9% were women, and for 4 (28.6%) DAH coincided with the debut of SLE. More than 80% of patients had renal involvement and thrombocytopenia. The most frequent manifestations were dyspnea (85.7%) and hypoxemia (100%), with the classic triad of hemoptysis, anemia and pulmonary infiltrates, appearing in 6 (46.2%) patients. The most frequently used treatments were glucocorticoids (85.7%) and cyclophosphamide (69.2%); plasmapheresis was utilized in 5 patients (35.7%) and 8, (57.1%) received intravenous immunoglobulins; 12 (85.7%) patients required admission to the ICU and 5 (35.7%) died. Tobacco use, history of lupus nephritis (LN), concomitant infection, and treatment with cyclophosphamide were more frequent in patients who died. Conclusions: DAH is rare in patients with SLE; in up to one-third of patients, it may appear at the onset of the disease. Some factors, such as smoking, a history of LN, treatment with cyclophosphamide, or concomitant infection, are more prevalent in patients with an unfavorable outcome.


  • Open Access

    Damage in a large systemic lupus erythematosus cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER) with emphasis on the cardiovascular system: a longitudinal analysis

    by Irene Altabás-González, Iñigo Rua-Figueroa, Coral Mouriño, Karen Roberts, Norman Jimenez, Julia Martinez-Barrio, María Galindo, Jaime Calvo Alén, Victor del Campo Pérez, Esther Uriarte Itzazelaia, et al.

    Objective To assess organ damage, with emphasis on the cardiovascular system, over the different stages of the disease in a large SLE cohort. Methods Multicentre, longitudinal study of a cohort of 4219 patients with SLE enrolled in the Spanish Society of Rheumatology Lupus Registry. Organ damage was ascertained using the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). We longitudinally analysed SDI (globally and for each domain) over time only in the 1274 patients whose dates of damage events had been recorded. Results During the first year after diagnosis of SLE, 20% of the 1274 patients presented with new damage manifestations. At years 2 and 3, new damage was recorded in 11% and 9% of patients. The annual percentage of patients with new damage after year 5 decreased to 5%. In the first year with the disease, most damage was accumulated in the musculoskeletal, neuropsychiatric and renal systems; in later stages, most damage was in the musculoskeletal, ocular and cardiovascular systems. Considering ‘cerebrovascular accident’ and ‘claudication for 6 months’ as cardiovascular items, the cardiovascular system was the second most affected system during the early stages of SLE, with 19% of the patients who presented with damage affected at first year after diagnosis. During the late stages, 20–25% of the patients presenting with new damage did so in this modified cardiovascular domain of the SDI. Conclusions New damage occurs mainly during the first year following diagnosis of SLE. Cardiovascular damage is relevant in both the early and the late stages of the disease. Strategies to prevent cardiovascular damage should be implemented early after diagnosis of SLE.


  • Rheumatoid meningitis: a case series report and review of modern therapeutic schemes and outcome

    by Carlos Serra Smith, Fernando José Montero Reyes, Ana Contreras Chicote, Julia Martínez Barrio, Mihaela Vieru, Isabel Herrera Herrera, Francisco Arias, Marisa Martínez Ginés, Jose Manuel García Domínguez

    Introduction Rheumatoid meningitis (RM) is an extremely rare extra-articular complication of rheumatoid arthritis (RA), with approximately 165 cases reported world-wide. RM exhibits a broad range of symptoms, with stroke-like episodes and seizures being the most common manifestations. The primary differential diagnoses include vascular and infectious diseases. The influence of immunomodulatory medications on the pathophysiology of RM remains unclear. There are no consensus guidelines on therapeutic regimen. Methods We present four patients with prior history of RA that developed different neurological syndromes in correlation to radiological leptomeningitis. Clinical presentations, comorbid conditions, supplementary diagnostic assessments, treatments, and prognosis are provided. A literature review of recent immunosuppressive management in RM patients was performed. Results Three patients presented to hospital with recurrent focal seizures. Only two suffered meningism, reporting headache and fever. Magnetic resonance imaging (MRI) showed different grades of leptomeningitis across all cases. Notably, three cases demonstrated bilateral involvement extending to the pachymeninges. Two patients exhibited pronounced CSF mononuclear inflammation while extended microbiological evaluations yielded negative results. Two patients required biopsy for confirmation. The initiation of immunosuppressive therapy marked a turning point for three patients who previously exhibited progressive deterioration. Mortality was absent in all cases. Conclusions Our experience remarks the elusive nature of RM. Rigorous exclusionary diagnostics are imperative to differentiate RM from mimicking conditions. Clinical manifestations oscillate between transient episodes and progressive neurological impairments, punctuated by frequent epileptic seizures. In scenarios where clinical worsening persists or where clinical and radiological evaluations are inconclusive, aggressive immunosuppressive therapy is recommended.


  • Open Access

    Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey’

    by Fernando Montero, Isabel Castrejón, Julia Martínez-Barrio, Juan Carlos Nieto-González, Javier Rivera, José María Álvaro-Gracia, Juan Molina Collada


  • Oral or pulse glucocorticoid use at the onset of giant cell arteritis and its influence on the risk of relapse: a retrospective study

    by Laura Trives-Folguera, Juan Molina-Collada, Katerine López, Javier Rivera, Belén Serrano-Benavente, Ana M. Anzola-Alfaro, Isabel Castrejón, José María Álvaro-Gracia, Julia Martínez-Barrio

    The objective is to investigate whether initial therapy with intravenous methylprednisolone pulses (ivMTP) or oral glucocorticoid (OG) influences the relapse rate in giant cell arteritis (GCA) patients. This is a retrospective observational study of patients with GCA from 2004 to 2021. Demographics, clinical and laboratory variables, cumulative glucocorticoid dose and relapse rate at 6-month follow-up defined according to EULAR recommendations were recorded. Univariate and multivariate logistic regression models were used to determine possible risk factors for relapse. A total of 74 GCA patients were included for analysis (54 (73%) female, mean (SD) age 77.2 (7.4) years). Overall, 47 (63.5%) patients received ivMTP at disease onset and 27 (36.5%) OG. Mean (SD) cumulative prednisone dose (mg) at 6-month follow-up was 3790.7 (1832.7) for patients with ivMTP vs 4298.1 (2930.6) for the OG group, p = 0.37. A total of 15 (20.3%) relapses occurred at 6-month follow-up. Relapse rates did not differ according to the initial therapy (19.1 vs 22.2%, respectively, p = 0.75). In the multivariate analysis, fever at disease onset (OR 4.837; CI 1.1–21.6) and dyslipidemia (OR 5.651; CI 1.1–28.4) were independent predictors for relapse. Initial therapy with ivMTP or OG does not influence the relapse rate of GCA patients. Fever at disease onset and dyslipidemia are independent predictors of disease relapse.


  • Open Access

    Impact of cardiovascular risk on the diagnostic accuracy of the ultrasound Halo Score for giant cell arteritis

    by Juan Molina-Collada, Katerine López Gloria, Isabel Castrejón, Juan Carlos Nieto-González, Julia Martínez-Barrio, Ana M. Anzola Alfaro, Javier Rivera, José María Álvaro-Gracia

    Objective: To evaluate the impact of cardiovascular risk (CVR) on the diagnostic accuracy of the ultrasonographic (US) Halo Score in patients with suspected giant cell arteritis (GCA). Methods: Retrospective observational study of patients referred to our US fast track clinic with suspected GCA for a 2-year period. The intima-media thickness (IMT) of cranial and extra-cranial arteries and the Halo Score was determined to assess the extent of vascular inflammation. The European Society of Cardiology Guidelines on CV Disease Prevention were used to define different categories of CVR and patients were classified according to the Systemic Coronary Risk Evaluation (SCORE). The gold standard for GCA diagnosis was clinical confirmation after a 6-month follow-up. Results: Of the 157 patients included, 47 (29.9%) had GCA after a 6-month follow-up. Extra-cranial artery IMT was significantly higher in patients with high/very high CVR than in those with low/moderate CVR, but only among patients without GCA. Non-GCA patients with high/very high CVR had also a significantly higher Halo Score in contrast with low/moderate CVR [9.38 (5.93) vs 6.16 (5.22); p = 0.007]. The area under the ROC curve of the Halo Score to identify GCA was 0.835 (95% CI 0.756–0.914), slightly greater in patients with low/moderate CVR (0.965 [95% CI 0.911–1]) versus patients with high/very high CVR (0.798 [95% CI 0.702–0.895]). A statistically weak positive correlation was found between the Halo Score and the SCORE (r 0.245; c = 0.002). Conclusions: Elevated CVR may influence the diagnostic accuracy of the US Halo Score for GCA. Thus, CVR should be taken into consideration in the US screening for GCA.


  • The role of ultrasound and FDG-PET/CT to detect extracranial artery involvement in patients with suspected large vessel vasculitis

    by Juan Molina-Collada, Isabel Castrejón, Javier Rivera, Julia Martínez-Barrio, Juan Carlos Nieto-González, Katerine López, Fernando Montero, Laura Trives, Carlos González, José María Álvaro-Gracia

    Objective: To assess the accuracy of ultrasound (US) versus fluorodeoxyglucose—positron emission tomography/computed tomography (FDG-PET/CT) to identify extracranial involvement in large vessel vasculitis (LVV). Methods: A retrospective observational study of patients with suspected LVV. All patients underwent US exam within 24 h per protocol. FDG-PET/CT was performed according to clinician criteria. The gold standard for LVV diagnosis was clinical confirmation after 6 months. Results: Of the 113 patients included (74.3% female, mean age 74 years), 37 (32.7%) were diagnosed with LVV after 6 months. The sensitivity and specificity of US were 86.5% and 96.1%, respectively. Only 12 (42.9%) of 28 patients undergoing a FDG-PET/CT per clinician criteria showed positive findings. The sensitivity and specificity of FDG-PET/CT for LVV were 61.1% and 90%, respectively. Taking FDG-PET/CT as the reference, US showed extracranial inflammation in 10/12 (83.3%) and detected 2 (12.5%) additional cases of extracranial involvement with negative FDG-PET/CT. Conversely, FDG-PET/CT was positive in two patients with negative US (one isolated aortitis and one aortoiliac involvement). Conclusions: US and FDG-PET/CT are both valid tools to detect extracranial involvement. The presence of US extracranial artery inflammation is consistent with FDG-PET/CT examination, although a negative US scan does not rule out extracranial involvement.


  • Importance of family planning in patients with immune-mediated inflammatory diseases: A multidisciplinary approach

    by Julia Martínez-Barrio, Juan Antonio Martínez López, María Galindo, Arantza Ais, Nuria Martínez Sánchez, Laura Cano